Search By:
Products
Injury
Topic
Company
Industry
Bayer AG might have harmed direct purchasers of Cipro when Bayer paid $400 million to generic drug manufactures not to develop a genetic alternative to Cipro.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topics
- Price Fixing
- Overcharging for Drug
Products or Services
- Cipro
- Doctors
- Hospitals
- Healthcare Organizations
Injury Type
- Monetary Loss
Investigation Details
This is an ongoing investigation and pending class action lawsuit against Bayer Corp., Barr Laboratories, Inc., Hoechst Marion Russell, Inc., and The Rugby Group on behalf of direct purchasers of the brand name drug Cipro, a form of ciprofloxacin hydrochloride.
Cipro is a billion-dollar-a-year antibiotic manufactured and sold by defendant Bayer Corporation. In 1997, Bayer and its parent company, defendant Bayer AG (collectively, 'Bayer'), agreed to pay $398 million over seven years to their generic competitors, defendants Barr Laboratories, Inc., Hoechst Marion Russell, Inc., and The Rugby Group, to prevent a less expensive, fully substitutable generic form of Cipro from entering the market, while permitting the generic competitors to share in Bayer's monopoly profits. This wrongfully blocked and delayed the market entry of lower-priced, but therapeutically equivalent, generic versions of Cipro, forcing all purchasers of Cipro to pay illegally inflated prices.
Do not change medications without first consulting your doctor.
Cipro is a billion-dollar-a-year antibiotic manufactured and sold by defendant Bayer Corporation. In 1997, Bayer and its parent company, defendant Bayer AG (collectively, 'Bayer'), agreed to pay $398 million over seven years to their generic competitors, defendants Barr Laboratories, Inc., Hoechst Marion Russell, Inc., and The Rugby Group, to prevent a less expensive, fully substitutable generic form of Cipro from entering the market, while permitting the generic competitors to share in Bayer's monopoly profits. This wrongfully blocked and delayed the market entry of lower-priced, but therapeutically equivalent, generic versions of Cipro, forcing all purchasers of Cipro to pay illegally inflated prices.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Bayer AG | Bayer AG manufactures pharmaceuticals and consumer products. |
| Barr Laboratories, Inc. | Barr Laboratories, Inc. is also known as Barr Pharmaceuticals. It manufactures and markets generic and proprietary pharmaceuticals. In 2008, Teva Pharmaceutical Industries Ltd acquired Barr Laboratories. |